The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 31 August 2004, www.theannals.com, DOI 10.1345/aph.1D616.
 The Annals of Pharmacotherapy: Vol. 38, No. 10, pp. 1660-1663. DOI 10.1345/aph.1D616
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kirian, M. A
Right arrow Articles by Fulco, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kirian, M. A
Right arrow Articles by Fulco, P. P.

OBJETIVO: Notificar el caso de un paciente que desarrolló pancreatitis tras el uso combinado de didanosina y tenofovir.

RESUMEN: Un hombre de 51 años de edad con infección por el HIV inició tratamiento con didanosina, tenofovir, lamivudina, estavudina, y efavirenz. El paciente recibió una dosis reducida de didanosina debido al potencial de interacción con tenofovir. A pesar del ajuste en la dosis de didanosina, el paciente desarrolló pancreatitis aguda 10 semanas después de haber comenzado los antirretrovirales. La pancreatitis resolvió espontáneamente tras abandonar los antirretrovirales.

CONCLUSIONES: Tenofovir y didanosina se pueden utilizar en combinación con mucha cautela como parte de la pauta antirretroviral. Cuando se utilizan en combinación, se recomienda reducir la dosis de didanosina a 650 mg para disminuir el potencial de toxicidad. Los profesionales sanitarios deben de ser conscientes de que puede ocurrir una interacción significativa entre estos medicamentos que produzca una pancreatitis, aún cuando se administre una dosis reducida de didanosina.

www.theannals.com, DOI 10.1345/aph.1D616


This article has been cited by other articles:


Home page
 J Int Assoc Physicians AIDS Care (Chic Ill)Home page
A. D. Luber
Pharmacokinetic Considerations for Selection of HAART in Treatment-Naive HIV-Infected Individuals, 2008: More Than It Seems?
J Int Assoc Physicians AIDS Care (Chic Ill), March 1, 2008; 7(1_suppl): 10 - 16.
[Abstract] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. Torti, G. Lapadula, P. Barreiro, V. Soriano, S. Mandalia, A. De Silvestri, F. Suter, F. Maggiolo, A. Antinori, F. Antonucci, et al.
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load
J. Antimicrob. Chemother., June 1, 2007; 59(6): 1141 - 1147.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kirian, M. A
Right arrow Articles by Fulco, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kirian, M. A
Right arrow Articles by Fulco, P. P.

homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.